Диссертация (1141143), страница 14
Текст из файла (страница 14)
398-403.9.Моисеев С.В. Антикоагуляция при кардиоверсии у больных сфибрилляцией предсердий // Клиническая фармакология и терапия.– 2014.–№ 4.– с. 17-22.10.Страхова К.В., Великова И.В., Мазур В.В. и др. Станнинг предсердийкак этап их обратного ремоделирования после восстановления синусового ритмау больных идиопатической фибрилляцией предсердий // Вестник аритмологии.–2010.– № 62.– c. 37–40.11.Сулимов В.А., Голицын С.П., Панченко Е.П., Попов С.В., РевишвилиА.Ш., Шубик Ю.В., Явелов И.С., Благова О.В., Галявич А.С., Гиляров М.Ю.,Дощицын В.Л., Дупляков Д.В., Зенин С.А., Канорский С.Г., Карпов Ю.А.,Кропачева Е.С., Мазур Н.А., Матюшин Г.В., Медведев М.М., Михайлов С.П. идр.
Диагностика и лечение фибрилляции предсердий. Рекомендации РКО, ВНОАИ АССХ // Российский кардиологический журнал.– 2013.– № 4 S3 (102) .– с. 1100.12.Явелов И.С. Кардиоверсия при использовании ривароксабана убольных с неклапанной фибрилляцией предсердий: результаты исследования XVERT // Атеротромбоз.– 2015.– № 1.– с. 24-30.13.Agarwal A.K., Venugopalan P. Left atrial spontaneous echo contrast inpatients with rheumatic mitral valve stenosis in sinus rhythm: relationship to mitralvalve and left atrial measurements // Int J Cardiol.
- 2001. - Vol.77. - p.63–68.14.Airaksinen K.E., Gronberg T., Nuotio I., Nikkinen M., Ylitalo A., BiancariF., Hartikainen J.E. Thromboembolic complications after cardioversion of acute atrialfibrillation: the FinCV (FinnishCardioVersion) study. // J Am Coll Cardiol.– 2013.–Vol. 62.– p. 1187–1192.15.Albers G.W., Dalen J.E., Laupacis A. et al. Antithrombotic Therapy inAtrial Fibrillation // Chest.– 2001.– Vol.119.– p.194–206.9716.Albers G.W., Diener H.C., Frison L., Grind M., Partridge S., HalperinJ.L., Horrow J., Olsson S.B., Petersen P., Vahanian A. SPORTIF Executive SteeringCommittee for the SPORTIF V Investigators. Ximelagatran vs.
warfarin for strokeprevention in patients with nonvalvular atrial fibrillation // JAMA. -2005. - Vol.293. p.690–698.17.Arias M.A., Casares-Medrano J., Pacho´n M., Puchol A. Silent embolismafter electrical cardioversion of atrial fibrillation: what does brain magnetic resonanceimaging provide? // Rev Esp Cardiol. -2012. - Vol.65. - p.489.18.Atrial Fibrillation Investigators: Atrial Fibrillation A.
A. S., Boston AreaAnticoagulation Trial for Atrial Fibrillation Study, Canadian Atrial FibrillationAnticoagulation Study et al. Risk Factors for Stroke and Efficacy of AntithromboticTherapy in Atrial Fibrillation: Analysis of Pooled Data From Five RandomizedControlled Trials // Arch Intern Med.– 1994.– Vol. 154.– p. 1449–1457.19.Bellotti P., Spirito P., Lupi G. et al. Left Atrial Appendage FunctionAssessed by Transesophageal Echocardiography Before and on the Day After ElectiveCardioversion for Nonvalvular Atrial Fibrillation// The American journal ofcardiology.– 1998.– Vol.
81.– p. 1199–1202.20.Berger M, Schweitzer P. Timing of thromboembolic events after electricalcardioversion of atrial fibrillation or flutter: a retrospective analysis // The Americanjournal of cardiology.– 1998.– Vol. 82.– p. 1545–1547.21.Binici Z., Intzilakis T., Nielsen O.W. et al. Excessive supraventricularectopic activity and increased risk of atrial fibrillation and stroke. // Circulation.–2010.– Vol.
121.– p. 1904-1911.22.Bjerkelund C.J., Orning O.M. The efficacy of anticoagulant therapy inpreventing embolism related to DC electrical conversion of atrial fibrillation // TheAmerican journal of cardiology.– 1969.– Vol. 23.– p. 208-216.23.Black I.W. Spontaneous echo contrast: where there’s smoke there’s fire //Echocardiography.– 2000.– Vol. 17.– p. 373–382.9824.Black I.W., Chesterman C.N., Hopkins A.P. et al.
Hematologic correlatesof left atrial spontaneous echo contrast and thromboembolism in nonvalvular atrialfibrillation // J Am Coll Cardiol.– 1993.– Vol. 21.– p. 451–457.25.Caldeira D., Costa J., Ferreira J.J., Lip G.Y., Pinto F.J. Non-vitamin Kantagonist oral anticoagulants in the cardioversion of patients with atrial fibrillation:systematic review and meta-analysis // Clin Res Cardiol.– 2015.– Vol.
104(7).– p. 582–590.26.Camm A.J., Lip G.Y., De Caterina R., Savelieva I. et al; ESC Committeefor Practice Guidelines (CPG). 2012 focused update of the ESC Guidelines for themanagement of atrial fibrillation: an update of the 2010 ESC Guidelines for themanagement of atrial fibrillation. Developed with the special contribution of theEuropean Heart Rhythm Association // European Heart Journal.– 2012.– Vol.33.– p.2719–2747.27.Cappato R., Ezekowitz M.D., Klein A.L., Camm A.J., Chang-Sheng Ma,Le Heuzey J.Y., Talajic M., Scanavacc M., Vardas P.E., Kirchhof P., Hemmrich M.,Lanius V., Meng I.L., Wildgoose P., van Eickel M., Hohnloser S.H. Rivaroxaban vs.vitamin K antagonists for cardioversion in atrial fibrillation // Eur Heart J.– 2014.–Vol. 35 (47).– p.
3346–3355.28.Chimowitz M.I., DeGeorgia M.A., Poole R.M. et al. Left atrialspontaneous echo contrast is highly associated with previous stroke in patients withatrial fibrillation or mitral stenosis // Stroke.– 1993.– Vol. 24.– p. 1015–1019.29.Ciolli A., De Sisti A., Montenero A.S. et al. Idiopathic atrial fibrillation ofrecent onset and atrial stunning: the echocardiographic evidence after pharmacologicalcardioversion // Cardiologia.– 1998.– Vol. 43.– p. 1077–1082.30.Coleman C., Khalaf S., Mould S., Wazni O., Kanj M., Saliba W.,Cantillon D.
Novel Oral Anticoagulants for DC Cardioversion Procedures: Utilizationand Clinical Outcomes Compared with Warfarin // Pacing Clin Electrophysiol.–2015.– Vol. 38(6).– p. 731–737.9931.Collins L.J., Silverman D.I., Douglas P.S. et al. Cardioversion ofnonrheumatic atrial fibrillation. Reduced thromboembolic complications with 4 weeksof precardioversion anticoagulation are related to atrial thrombus resolution //Circulation.– 1995.– Vol. 92.– p.
160–163.32.Connolly S., Pogue J., Hart R., Pfeffer M., Hohnloser S., Chrolavicius S.,Yusuf S. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation inthe Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of VascularEvents (ACTIVE W): a randomised controlled trial // Lancet.– 2006.– Vol. 367.– p.1903-1912.33.Connolly S.J., Ezekowitz M.D., Yusuf S., Eikelboom J., Oldgren J.,Parekh A., Pogue J., Reilly P.A., Themeles E., Varrone J., Wang S., Alings M., XavierD., Zhu J., Diaz R., Lewis B.S., Darius H., Diener H.C., Joyner C.D., Wallentin L.Dabigatran versus warfarin in patients with atrial fibrillation.
N Engl J Med.– 2009.–Vol. 361.– p. 1139-1151.34.Connolly S.J., Pogue J., Hart R.G., Hohnloser S.H., Pfeffer M.,Chrolavicius S., Yusuf S. Effect of clopidogrel added to aspirin in patients with atrialfibrillation // N Engl J Med.– 2009.– Vol. 360.– p. 2066–2078.35.Connolly S.J., Wallentin L., Ezekowitz M.D., Eikelboom J., Oldgren J.,Reilly P.A., Brueckmann M., Pogue J., Alings M., Amerena J.V., Avezum A.,Baumgartner I., Budaj A.J., Chen J.H., Dans A.L., Darius H., Di Pasquale G., FerreiraJ., Flaker G.C., Flather M.D., Franzosi M.G., Golitsyn S.P., Halon D.A., HeidbuchelH., Hohnloser S.H., Huber K., Jansky P., Kamensky G., Keltai M., Kim S.S., Lau C.P.,Le Heuzey J.Y., Lewis B.S., Liu L., Nanas J., Omar R., Pais P., Pedersen K.E., PiegasL.S., Raev D., Smith P.J., Talajic M., Tan R.S., Tanomsup S., Toivonen L., VinereanuD., Xavier D., Zhu J., Wang S.Q., Duffy C.O., Themeles E., Yusuf S. The long-termmulticenter observational study of dabigatran treatment in patients with atrialfibrillation (RELY-ABLE) study // Circulation.– 2013.– Vol.
128.– p. 237–243.10036.de Divitiis M., Omran H., Rabahieh R. et al. Right atrial appendagethrombosis in atrial fibrillation: it's frequency and its clinical predictors // Am JCardiol.– 1998.– Vol. 87.– p. 1023–1028.37.De Luca I., Sorino M., De Luca L., Colonna P., Del Salvatore B., CorlianòL. Pre- and post-cardioversion transesophageal echocardiography for briefanticoagulation therapy with enoxaparin in atrial fibrillation patients: a prospectivestudy with a 1-year follow-up // Int J Cardiol.– 2005.– Vol.
102(3).– p. 447–454.38.De Maria A.N., Lies J.E., King J.F., Miller R.R., Amsterdam E.A., MasonD.T. Echographic assessment of atrial transport, mitral movement, and ventricularperformance following electroversion of supraventricular arrhythmias // Circulation.–1975.– Vol. 51.– p. 273–282.39.Dunn M.I., Marcum J.L. Atrial Mechanical Performance FollowingInternal and External Cardioversion of Atrial Fibrillation // Chest.– 2002.– Vol.
121.–p.1–3.40.Eikelboom J.W., Connolly S. J., Brueckmann M. et al. Dabigatran versuswarfarin in patients with mechanical heart valves // The New England Journal ofMedicine.– 2013.– Vol. 369.– p. 1206–1214.41.Executive Steering Committee for the SPORTIF III Investigators.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
